Foreign pharma investors in Uzbekistan face layered currency control rules governing dividend repatriation and profit transfer. Here is what in-house counsel needs to know. Make an enquiry.
Foreign pharmaceutical companies investing in Uzbekistan routinely underestimate the practical complexity of moving profits out of the country. The statutory framework is broadly permissive — Uzbekistan's currency legislation formally guarantees the right of foreign investors to repatriate profits and dividends — yet the operational reality involves banking procedures, documentary requirements, and sector-specific licensing conditions that can extend the timeline for a cross-border transfer by weeks or, in more complex cases, months. For in-house counsel managing a pharmaceutical subsidiary or a joint venture in Uzbekistan, understanding where the legal framework ends and where banking and regulatory practice begins is the essential starting point.
Uzbekistan's currency control framework is built on a body of legislation that has undergone sustained liberalisation since 2017, when the government initiated a broad programme of foreign exchange reform. The core statutory guarantee for foreign investors — the right to repatriate profits, dividends, royalties, and proceeds from the sale of assets — is enshrined in the legislation governing foreign investment, and it is reinforced by bilateral investment treaties to which Uzbekistan is party. For investors from Western Europe, Korea, and other major pharmaceutical source markets, the relevant treaty network provides an additional layer of protection that, in practice, matters when banking-level obstacles arise.
The guarantee, however, operates within a framework of conditions. Foreign legal entities and their Uzbek subsidiaries are subject to the general currency control regime, which requires that cross-border payments be routed through authorised banks — commercial banks holding the relevant foreign exchange licences. These banks are required to verify the documentary basis for each transfer before releasing funds. The regulatory authority overseeing this system is the Central Bank of Uzbekistan, which publishes instructions and guidance that authorised banks are required to follow. The practical consequence is that the legal guarantee of repatriation is exercised through a bank compliance process, not through a direct statutory right that operates automatically.
For pharmaceutical companies specifically, an additional layer applies. The sector is subject to licensing and regulatory oversight by the relevant public health and pharmaceutical regulators, and certain payments — in particular, royalties for use of intellectual property embedded in pharmaceutical products, and payments for technology transfer — may be scrutinised under both the currency control framework and the licensing framework simultaneously. In-house counsel should be aware that a transfer that is structurally sound under currency law may still face delay if the underlying commercial contract has not been registered or approved in a form recognised by the banking compliance system.
The documentary requirements for a profit repatriation transfer in Uzbekistan are defined by Central Bank instructions and, in practice, supplemented by the internal compliance procedures of individual authorised banks. While the statutory framework sets a ceiling on what banks may demand, the floor is determined by banking practice, and there is meaningful variation between institutions.
For a dividend transfer from an Uzbek limited liability company or joint-stock company to a foreign parent, the core documentary package typically includes: a certified copy of the corporate decision authorising the dividend distribution; financial statements demonstrating the availability of distributable profits; confirmation that all Uzbek tax obligations have been settled in respect of the period from which profits are being distributed; and the dividend withholding tax certificate, evidencing payment at the applicable rate. Where a double tax treaty applies — Uzbekistan has an active treaty network with Russia, Germany, South Korea, and several other significant pharmaceutical investor jurisdictions — the investor must typically obtain advance confirmation from the Uzbek tax authority that the reduced treaty rate applies, rather than the standard domestic withholding rate. This confirmation process itself has a defined administrative timeline, and it is a common source of delay for investors who initiate the repatriation process without completing tax clearance first.
For royalty and licence fee transfers — which are structurally important in the pharmaceutical sector, where international brand owners and originator companies often license their product registrations, trade marks, and manufacturing know-how to Uzbek subsidiaries or joint venture partners — the documentary requirements include the underlying licence agreement (which must typically be registered in Uzbekistan as part of the technology transfer or IP licensing regime) and evidence that the payment corresponds to the registered terms. Payments that exceed the registered contractual terms, or that are made under agreements not registered in the required form, are routinely queried by banks and may be declined pending regularisation.
The timeline for processing a straightforward dividend transfer at an authorised bank — assuming all documentation is in order — is generally between five and fifteen business days. More complex transactions, including those involving intellectual property payments or those where the withholding tax clearance has not been obtained in advance, routinely extend beyond this. Investors who plan a year-end distribution and initiate the process in the fourth quarter without adequate lead time frequently encounter the additional complication that bank resources are concentrated on reporting obligations in that period, which further extends practical timelines.
"The most predictable problems in Uzbekistan repatriation are not legal — they are procedural: investors arrive at the bank with an incomplete documentary package that could have been assembled months earlier." — Nodira Yusupova, Contributing Regional Analyst — Uzbekistan, Vetrov & Partners
The pharmaceutical sector in Uzbekistan sits within a regulatory framework that extends well beyond the general business environment. Product registration, pricing controls for essential medicines, licensing of manufacturing facilities, and requirements for local clinical data in certain registration categories all create an intersecting regulatory landscape that directly affects the commercial contracts underlying a foreign investor's profit flows.
For the purposes of currency control and repatriation, the most practically significant sector-specific issue is the treatment of payments under supply contracts between a foreign parent company and its Uzbek affiliate. Uzbekistan's currency control framework requires that proceeds from the export of goods and services be repatriated within defined timelines. For pharmaceutical companies operating distribution models under which the Uzbek subsidiary imports finished goods from the foreign parent, the payment flows run in the opposite direction — outward, from Uzbekistan to the foreign supplier. These outward payments are subject to verification that the goods have been received and cleared through customs, and banks will require documentation of customs clearance alongside the payment instruction. Where product registration requirements mean that a consignment has been held pending regulatory review, the documentary chain for the payment may be incomplete, creating a de facto delay in the payment flow.
The pricing dimension adds a further layer of complexity specific to the sector. Uzbekistan maintains price controls on a list of essential medicines, and the regulated prices for such medicines affect the revenue base of the Uzbek subsidiary. Where the transfer price between a foreign parent and its Uzbek affiliate is subject to transfer pricing scrutiny — and Uzbekistan has a transfer pricing framework applicable to related-party transactions — the tax authority's position on the arm's-length price of the goods can directly affect the distributable profit figure and, consequently, the amount available for repatriation. Investors who have not conducted a transfer pricing analysis at the point of setting their intercompany pricing are exposed to adjustment on audit, which can reduce the distributable profit retrospectively and create a divergence between the profits expected for repatriation and those legally available.
Manufacturing investors face an additional consideration. Companies that have established or are establishing pharmaceutical manufacturing operations in Uzbekistan — a priority area under the government's industrial development programme — may benefit from specific investment incentive regimes, including customs and tax preferences. These incentive packages are typically contained in formal investment agreements with the government, and the terms of those agreements may include conditions on the reinvestment of profits in the early years of the investment. Where such conditions exist, they operate as a contractual limitation on repatriation that sits alongside the statutory currency control framework, and must be reviewed with equal care.
For foreign pharmaceutical investors whose Uzbekistan operations are held through a Russian intermediate holding company, or who have historically used Russian banking channels for CIS regional payments, the post-2022 environment has introduced significant structural complexity. Russian correspondent banking restrictions and the altered settlement landscape for cross-border payments between Russia and third countries have made Russian-intermediated structures less straightforward in practice, and a number of multinational investors have reassessed their regional holding and payment routing structures as a result.
Uzbekistan is not a member of the Eurasian Economic Union, which means that the EAEU's internal rules on capital movements do not apply between Russia and Uzbekistan in the same way as they apply between EAEU members. Uzbekistan is a CIS member, and certain CIS-level agreements on investment protection and currency arrangements are relevant, but the practical effect of CIS membership on cross-border payment flows is more limited than the EAEU framework. The bilateral investment treaty between Russia and Uzbekistan — and, where applicable, between the investor's home country and Uzbekistan — remains the primary treaty instrument governing investor protection, including protection of repatriation rights.
For investors considering or maintaining third-country holding structures — for example, through jurisdictions such as the Netherlands, the UAE, or Cyprus — the primary currency control consideration in Uzbekistan is whether the holding entity qualifies as a foreign investor under Uzbek law for purposes of the repatriation guarantee. The broad definition of foreign investor in Uzbekistan's investment legislation generally captures corporate entities incorporated outside Uzbekistan, irrespective of the jurisdiction of incorporation, provided the investment is made from abroad. The availability of treaty protection for the repatriation right, however, depends on the treaty network of the specific holding jurisdiction, and the choice of holding jurisdiction should be informed by treaty analysis at the outset.
Banking channel selection is a practical decision that deserves more attention than it typically receives at the planning stage. Authorised banks in Uzbekistan vary in their correspondent banking relationships, their familiarity with specific foreign investor jurisdictions, and the speed and reliability of their international payment processing. For pharmaceutical companies with recurring royalty or dividend payment flows, establishing the banking relationship and testing the payment channel with a smaller transaction before the first significant repatriation is a measure that experienced practitioners consistently recommend.
For cross-border matters with a Russian dimension — including structures involving Russian holding companies, Russian pharmaceutical market participants operating in Uzbekistan, or payment flows transiting through Russian banking channels — Vetrov & Partners advises on the Russian law dimension and coordinates with Uzbekistan-qualified regional counsel. Our Tax practice for Uzbekistan covers the structuring and advisory aspects, and our Corporate & Joint Ventures practice addresses the entity-level framework for investors considering or revisiting their Uzbek structure.
The practical steps for a foreign pharmaceutical company seeking to establish a sustainable repatriation framework in Uzbekistan follow a clear sequence, even if the specific legal and procedural content of each step requires jurisdiction-specific advice.
The starting point is a review of the corporate and contractual structure through which the Uzbek operation is held and through which commercial flows are documented. This review should confirm: that the Uzbek entity is correctly constituted as a foreign-invested entity for purposes of the investment legislation; that intercompany agreements — supply agreements, licence agreements, service agreements, and management fee arrangements — are documented, registered where registration is required, and structured at arm's-length prices supportable under the transfer pricing framework; and that the dividend distribution mechanism is clear in the corporate documents.
The second step is engagement with the applicable double tax treaty and, where relevant, the advance confirmation procedure with the Uzbek tax authority for the treaty withholding rate. This step should be initiated at least three to four months before the intended distribution date, to allow time for the administrative process and any queries from the tax authority.
The third step is the selection and qualification of an authorised bank, and the assembly of the documentary package required for the specific payment type. For recurring flows — quarterly royalties, annual dividends — establishing a documented process with the bank, including an agreed checklist of required documents, is a practical efficiency measure that reduces the risk of delay.
Fourth: investors with operations in the pharmaceutical sector should conduct a specific review of their product registration and pricing arrangements to confirm that the commercial contracts underlying the payment flows are consistent with the regulatory framework. Where product pricing is controlled, the profitability assumptions embedded in the intercompany structure should be reviewed against the regulated pricing environment.
Fifth: for investors who have entered into investment agreements with the Uzbek government, the terms of those agreements — including any profit reinvestment conditions — should be reviewed and mapped against the proposed repatriation schedule before any transfer is initiated. A breach of an investment agreement condition is a far more serious matter than a documentary deficiency at the bank, and the risk is not always visible from the face of the currency control framework.
The Regulatory & Licensing practice for Uzbekistan and the Market Entry & Company Formation practice provide the broader context for investors at an earlier stage of the market entry process. For investors already operational in Uzbekistan and seeking to optimise their existing structure, the Tax practice is the appropriate entry point.
Q: What is the legal basis for the right of a foreign pharmaceutical company to repatriate profits from Uzbekistan?
A: Uzbekistan's foreign investment legislation formally guarantees foreign investors the right to repatriate profits, dividends, royalties, and proceeds from asset disposals, without statutory limitation on amount. The guarantee is reinforced by a network of bilateral investment treaties. In practice, the right is exercised through the authorised bank system: the investor's Uzbek entity initiates the transfer through an authorised bank, which verifies the documentary package before releasing the funds. The guarantee does not operate as an automatic payment mechanism — it operates as a right not to be denied a transfer that meets the applicable documentary and tax clearance requirements. For pharmaceutical companies, additional documentation related to product registration and intercompany contract registration may also be required by the bank's compliance system before the transfer is processed.
Q: What withholding tax rate applies to dividends paid to a foreign parent company, and how is a treaty rate obtained?
A: The standard domestic withholding tax rate on dividends paid to non-resident shareholders in Uzbekistan is defined in the tax legislation and has historically been in the range of five to ten per cent, depending on the applicable provisions at the time of distribution. Where a double tax treaty between Uzbekistan and the shareholder's jurisdiction of residence provides for a reduced rate, the investor must apply to the Uzbek tax authority for advance confirmation of the treaty rate before the dividend is paid. The confirmation process has a defined administrative timeline under Uzbek procedural rules, and it is this process — not the treaty rate itself — that most commonly causes delay. Investors who initiate tax clearance at least three months before the intended distribution date are substantially less likely to experience timing problems as a result of this step.
Q: How does Uzbekistan's transfer pricing framework affect the pharmaceutical sector specifically?
A: Uzbekistan has a transfer pricing framework applicable to transactions between related parties — including transactions between a foreign parent company and its Uzbek subsidiary. For pharmaceutical companies, the most sensitive transfer pricing categories are: the price of finished pharmaceutical goods supplied from the foreign parent to the Uzbek entity for onward distribution; royalties and licence fees charged for the use of product registrations, trade marks, and manufacturing know-how; and management and service fees. The tax authority may audit these prices and adjust them to an arm's-length standard if the documented prices are found to deviate from market levels. An upward adjustment to the price of imported goods, or a downward adjustment to royalties, reduces the distributable profit of the Uzbek entity and consequently reduces the amount available for repatriation. A contemporaneous transfer pricing analysis — prepared before the intercompany prices are set — is the primary risk management tool.
Q: What documentation does an authorised bank require for a royalty or licence fee payment from an Uzbek pharmaceutical entity to its foreign licensor?
A: The documentary requirements vary between authorised banks, but the core package for an outward royalty payment typically includes: the underlying licence or technology transfer agreement, in a form registered with the relevant Uzbek authority where registration is required; evidence that the royalty calculation corresponds to the registered contractual terms; confirmation that the agreement has not been modified since registration in a way that affects the payment terms; and, where applicable, confirmation that the intellectual property being licensed is registered in Uzbekistan (for trade marks) or that the technology transfer has been notified to the relevant authority (for know-how and manufacturing processes). For pharmaceutical companies, the registration of product-related intellectual property in Uzbekistan through the relevant registry is a prerequisite for royalty payments in respect of that intellectual property, and gaps in the IP registration portfolio translate directly into gaps in the ability to make lawful outward payments.
Q: What practical steps should a foreign pharmaceutical company take to minimise delays in repatriation from Uzbekistan?
A: Five practical measures reduce the risk of delay materially. First, complete the corporate and contractual documentation review before the first commercial year closes — not during the repatriation cycle. Second, initiate the double tax treaty confirmation process with the Uzbek tax authority at least three months before the intended distribution. Third, select the authorised bank based on its international payment track record and its familiarity with the investor's home jurisdiction, and establish the payment channel with a test transaction before initiating a significant transfer. Fourth, confirm that all intercompany agreements are registered in the required form and that the contractual terms match the payment instructions being submitted to the bank. Fifth, review investment agreement conditions — if the operation is supported by a government investment agreement — to confirm that no reinvestment condition applies to the proposed distribution.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry